In contrast, sodium–glucose cotransporter‐2 (SGLT2) inhibitors show no significant effect on overall stroke risk but consistently provide cardiovascular and renal benefits, including reduced heart failure and kidney events [148]. This evidence concerns the gene SLC5A2 and heart failure.